Outcomes
Three of the 57 patients (5%) had concurrent diagnoses of NLPHL; all three were treated with chemotherapy. Another three patients (5%) had completed therapy for prior history of malignancy two or more years prior to PTGC diagnosis; one with recurrent NLPHL, one with classic Hodgkin lymphoma (CHL), and one with T-cell/histiocyte-rich large B-cell lymphoma. No patients went on to be diagnosed with a subsequent malignancy during the study period, but 3/57 (5%) patients had recurrent PTGC. Repeat LN biopsy for these three individuals was performed at intervals of three months, four months, and six years from the first biopsy.
One patient had prior history of common variable immunodeficiency (CVID) managed at an outside center and one had history of refractory Evans syndrome treated with steroids and rituximab; due to history of bulky lymphadenopathy, this patient was being evaluated for ALPS. An additional patient developed a subsequent diagnosis of Type 1 diabetes mellitus during the inclusion period. No other immune-mediated or lymphoproliferative conditions were documented in these patients during the inclusion period.